By using this site, you are consenting to our use of cookies. To find out more visit our privacy policy.
Includes articles, courses, and CPGs. Unlimited access for APTA members.
Jan 31, 2025/News
Our most popular courses of the year covered topics from payment and pharmacology to telehealth and screenings.
Mar 1, 2021/Open Access
This PowerPoint presentation provides both and overview and specific information about physical therapy education, application requirements, specialties and professional opportunities for students interested in applying to DPT and PTA education programs.
Jul 31, 2018/Article
This year's Mercer–Marquette Challenge broke many milestones and records. In celebrating its 30th year, the Challenge reached a lifetime total of more than $4 million. Adding to the accomplishments, a record-breaking 178 schools participated this year and raised $328,456. This year's top 3 schools are:
Apr 10, 2020/News
It can't be stressed enough: Individual states are the decision-makers around much of what PTs and PTAs can and can't do in response to the COVID-19 pandemic. These regularly updated resources can help you make fact-based practice decisions.
May 25, 2017/Test & Measure
This is a measure of disability and symptoms in patients with musculoskeletal disorders that is region specific to the upper limb.
Nov 20, 2018/Perspective
It must be one alliance between the patient, PT, and PTA.
Sep 28, 2021/Roundup
We honored our past, thought about our future, and had some good times along the way.
Jun 1, 2020/Article
As the country moves to reopen gradually, rules, regulations, policies, and recommendations are swiftly being amended, but valid concerns remain about how to safely run an outpatient facility during a pandemic.
Apr 26, 2022/News
The APTA program to nurture a diverse range of leaders and thinkers earned it a top spot among associations across the country.
Oct 1, 2021/Podcast
Defining moments can come more than once, a move to America, the birth of a baby, starting a practice, and a being thrown a curveball.